Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Peregrine looks to redefine bavituximab as immunotherapy

23:35 EDT 14 Jul 2013 | SCRIP

Tustin, California-based Peregrine is pressing forward with a Phase III clinical trial that pairs its phosphatidylserine (PS)-targeting monoclonal antibody with the chemotherapeutic agent docetaxel, but the company will continue a review of preclinic...

Original Article: Peregrine looks to redefine bavituximab as immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Peregrine looks to redefine bavituximab as immunotherapy"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story